The global Next Generation-based RNA sequencing market is expected to grow at a CAGR of 16.5% during the forecast period, from 2021 to 2030. The market is driven by the increasing demand for high-throughput sequencing technologies in various research and clinical applications such as transcriptome epigenetics, small RNA, and others. The increasing adoption of next generation sequencing technologies in various research and clinical applications such as transcriptome epigenetics, small RNA, and others are driving the growth of this market.
The global Next Generation-based RNA sequencing market is segmented on the basis of type (SBS vs SMRT), application (transcriptome epigenetics vs small RNAs), and region (North America vs Latin America vs Europe vs Asia Pacific & Middle East & Africa). North America accounted for the largest share in terms of revenue share in 2017 owing to its large number of biotechnology companies that offer next generation sequencing services. However, Asia Pacific is expected to grow at a higher CAGR during the forecast period due to its growing healthcare sector with an increased focus on personalized medicine which will drive demand for next generation sequencing technologies.
Some Of The Growth Factors Of This Market:
- The market for NGS-based RNA-seq is expected to grow due to the increasing demand for personalized medicine and the need for accurate diagnosis of diseases.
- The market growth will be driven by the increasing number of research and development activities in this field, which will lead to new product launches and innovations in this field.
- Increasing investments in research and development activities will also drive the growth of this market during the forecast period, as it leads to new product launches and innovations in this field.
- Increasing adoption rates among healthcare providers are also driving the growth of this market during the forecast period.
Industry Growth Insights published a new data on “NGS-based RNA-seq Market”. The research report is titled “NGS-based RNA-seq Market research by Types (SBS, SMRT), By Applications (Transcriptome Epigenetics, Small RNA), By Players/Companies Illumina, Thermo Fisher Scientific, Pacific Biosciences Of California, Qaigen, F. Hoffmann-La Roche, Agilent Technologies, Oxford Nanopore Technologies, Perkinelmer, Eurofins Scientific, Gatc Biotech, Macrogen”.
Scope Of The Report
Report Attributes
Report Details
Report Title
NGS-based RNA-seq Market Research Report
By Type
SBS, SMRT
By Application
Transcriptome Epigenetics, Small RNA
By Companies
Illumina, Thermo Fisher Scientific, Pacific Biosciences Of California, Qaigen, F. Hoffmann-La Roche, Agilent Technologies, Oxford Nanopore Technologies, Perkinelmer, Eurofins Scientific, Gatc Biotech, Macrogen
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
232
Number of Tables & Figures
163
Customization Available
Yes, the report can be customized as per your need.
Global NGS-based RNA-seq Market Report Segments:
The global NGS-based RNA-seq market is segmented on the basis of:
Types
SBS, SMRT
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Transcriptome Epigenetics, Small RNA
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Illumina
- Thermo Fisher Scientific
- Pacific Biosciences Of California
- Qaigen
- F. Hoffmann-La Roche
- Agilent Technologies
- Oxford Nanopore Technologies
- Perkinelmer
- Eurofins Scientific
- Gatc Biotech
- Macrogen
Highlights of The NGS-based RNA-seq Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- SBS
- SMRT
- By Application:
- Transcriptome Epigenetics
- Small RNA
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the NGS-based RNA-seq Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
NGS-based RNA-seq is a sequencing technique that uses next generation sequencing (NGS) technology to generate high quality, sequence data from samples. NGS-based RNA-seq can be used to identify and quantify the expression of specific genes in a sample.
Some of the major companies in the ngs-based rna-seq market are Illumina, Thermo Fisher Scientific, Pacific Biosciences Of California, Qaigen, F. Hoffmann-La Roche, Agilent Technologies, Oxford Nanopore Technologies, Perkinelmer, Eurofins Scientific, Gatc Biotech, Macrogen.
The ngs-based rna-seq market is expected to register a CAGR of 16.5%.
1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. NGS-based RNA-seq Market Overview
4.1. Introduction
4.1.1. Market Taxonomy
4.1.2. Market Definition
4.2. Macro-Economic Factors
4.2.1. Industry Outlook
4.3. NGS-based RNA-seq Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Opportunity
4.3.4. Market Trends
4.4. NGS-based RNA-seq Market - Supply Chain
4.5. Global NGS-based RNA-seq Market Forecast
4.5.1. NGS-based RNA-seq Market Size (US$ Mn) and Y-o-Y Growth
4.5.2. NGS-based RNA-seq Market Size (000 Units) and Y-o-Y Growth
4.5.3. NGS-based RNA-seq Market Absolute $ Opportunity
5. Global NGS-based RNA-seq Market Analysis and Forecast by Type
5.1. Market Trends
5.2. Introduction
5.2.1. Basis Point Share (BPS) Analysis by Type
5.2.2. Y-o-Y Growth Projections by Type
5.3. NGS-based RNA-seq Market Size and Volume Forecast by Type
5.3.1. SBS
5.3.2. SMRT
5.4. Absolute $ Opportunity Assessment by Type
5.5. Market Attractiveness/Growth Potential Analysis by Type
6. Global NGS-based RNA-seq Market Analysis and Forecast by Application
6.1. Market Trends
6.2. Introduction
6.2.1. Basis Point Share (BPS) Analysis by Application
6.2.2. Y-o-Y Growth Projections by Application
6.3. NGS-based RNA-seq Market Size and Volume Forecast by Application
6.3.1. Transcriptome Epigenetics
6.3.2. Small RNA
6.4. Absolute $ Opportunity Assessment by Application
6.5. Market Attractiveness/Growth Potential Analysis by Application
7. Global NGS-based RNA-seq Market Analysis and Forecast by Sales Channel
7.1. Market Trends
7.2. Introduction
7.2.1. Basis Point Share (BPS) Analysis by Sales Channel
7.2.2. Y-o-Y Growth Projections by Sales Channel
7.3. NGS-based RNA-seq Market Size and Volume Forecast by Sales Channel
7.3.1. Manufacturer/Distributor/Service Provider
7.3.2. Aftermarket
7.4. Absolute $ Opportunity Assessment by Sales Channel
7.5. Market Attractiveness/Growth Potential Analysis by Sales Channel
8. Global NGS-based RNA-seq Market Analysis and Forecast by Region
8.1. Market Trends
8.2. Introduction
8.2.1. Basis Point Share (BPS) Analysis by Region
8.2.2. Y-o-Y Growth Projections by Region
8.3. NGS-based RNA-seq Market Size and Volume Forecast by Region
8.3.1. North America
8.3.2. Latin America
8.3.3. Europe
8.3.4. Asia Pacific
8.3.5. Middle East and Africa (MEA)
8.4. Absolute $ Opportunity Assessment by Region
8.5. Market Attractiveness/Growth Potential Analysis by Region
8.6. Global NGS-based RNA-seq Demand Share Forecast, 2019-2026
9. North America NGS-based RNA-seq Market Analysis and Forecast
9.1. Introduction
9.1.1. Basis Point Share (BPS) Analysis by Country
9.1.2. Y-o-Y Growth Projections by Country
9.2. North America NGS-based RNA-seq Market Size and Volume Forecast by Country
9.2.1. U.S.
9.2.2. Canada
9.3. Absolute $ Opportunity Assessment by Country
9.4. North America NGS-based RNA-seq Market Size and Volume Forecast by Application
9.4.1. Transcriptome Epigenetics
9.4.2. Small RNA
9.5. Basis Point Share (BPS) Analysis by Application
9.6. Y-o-Y Growth Projections by Application
9.7. North America NGS-based RNA-seq Market Size and Volume Forecast by Type
9.7.1. SBS
9.7.2. SMRT
9.8. Basis Point Share (BPS) Analysis by Type
9.9. Y-o-Y Growth Projections by Type
9.10. Market Attractiveness/Growth Potential Analysis
9.10.1. By Country
9.10.2. By Product Type
9.10.3. By Application
9.10.4. By Sales Channel
9.11. North America NGS-based RNA-seq Demand Share Forecast, 2019-2026
10. Latin America NGS-based RNA-seq Market Analysis and Forecast
10.1. Introduction
10.1.1. Basis Point Share (BPS) Analysis by Country
10.1.2. Y-o-Y Growth Projections by Country
10.1.3. Latin America Average Pricing Analysis
10.2. Latin America NGS-based RNA-seq Market Size and Volume Forecast by Country
10.2.1. Brazil
10.2.2. Mexico
10.2.3. Rest of Latin America
10.3. Absolute $ Opportunity Assessment by Country
10.4. Latin America NGS-based RNA-seq Market Size and Volume Forecast by Application
10.4.1. Transcriptome Epigenetics
10.4.2. Small RNA
10.5. Basis Point Share (BPS) Analysis by Application
10.6. Y-o-Y Growth Projections by Application
10.7. Latin America NGS-based RNA-seq Market Size and Volume Forecast by Type
10.7.1. SBS
10.7.2. SMRT
10.8. Basis Point Share (BPS) Analysis by Type
10.9. Y-o-Y Growth Projections by Type
10.10. Market Attractiveness/Growth Potential Analysis
10.10.1. By Country
10.10.2. By Product Type
10.10.3. By Application
10.10.4. By Sales Channel
10.11. Latin America NGS-based RNA-seq Demand Share Forecast, 2019-2026
11. Europe NGS-based RNA-seq Market Analysis and Forecast
11.1. Introduction
11.1.1. Basis Point Share (BPS) Analysis by Country
11.1.2. Y-o-Y Growth Projections by Country
11.1.3. Europe Average Pricing Analysis
11.2. Europe NGS-based RNA-seq Market Size and Volume Forecast by Country
11.2.1. Germany
11.2.2. France
11.2.3. Italy
11.2.4. U.K.
11.2.5. Spain
11.2.6. Russia
11.2.7. Rest of Europe
11.3. Absolute $ Opportunity Assessment by Country
11.4. Europe NGS-based RNA-seq Market Size and Volume Forecast by Application
11.4.1. Transcriptome Epigenetics
11.4.2. Small RNA
11.5. Basis Point Share (BPS) Analysis by Application
11.6. Y-o-Y Growth Projections by Application
11.7. Europe NGS-based RNA-seq Market Size and Volume Forecast by Type
11.7.1. SBS
11.7.2. SMRT
11.8. Basis Point Share (BPS) Analysis by Type
11.9. Y-o-Y Growth Projections by Type
11.10. Market Attractiveness/Growth Potential Analysis
11.10.1. By Country
11.10.2. B Product Type
11.10.3. By Application
11.10.4. By Sales Channel
11.11. Europe NGS-based RNA-seq Demand Share, 2019-2026
12. Asia Pacific NGS-based RNA-seq Market Analysis and Forecast
12.1. Introduction
12.1.1. Basis Point Share (BPS) Analysis by Country
12.1.2. Y-o-Y Growth Projections by Country
12.1.3. Asia Pacific Average Pricing Analysis
12.2. Asia Pacific NGS-based RNA-seq Market Size and Volume Forecast by Country
12.2.1. China
12.2.2. Japan
12.2.3. South Korea
12.2.4. India
12.2.5. Australia
12.2.6. Rest of Asia Pacific (APAC)
12.3. Absolute $ Opportunity Assessment by Country
12.4. Asia Pacific NGS-based RNA-seq Market Size and Volume Forecast by Application
12.4.1. Transcriptome Epigenetics
12.4.2. Small RNA
12.5. Basis Point Share (BPS) Analysis by Application
12.6. Y-o-Y Growth Projections by Application
12.7. Asia Pacific NGS-based RNA-seq Market Size and Volume Forecast by Type
12.7.1. SBS
12.7.2. SMRT
12.8. Basis Point Share (BPS) Analysis by Type
12.9. Y-o-Y Growth Projections by Type
12.10. Market Attractiveness/Growth Potential Analysis
12.10.1. By Country
12.10.2. By Product Type
12.10.3. By Application
12.10.4. By Sales Channel
12.11. Asia Pacific NGS-based RNA-seq Demand Share, 2019-2026
13. Middle East & Africa NGS-based RNA-seq Market Analysis and Forecast
13.1. Introduction
13.1.1. Basis Point Share (BPS) Analysis by Country
13.1.2. Y-o-Y Growth Projections by Country
13.1.3. Asia Pacific Average Pricing Analysis
13.2. Middle East & Africa NGS-based RNA-seq Market Size and Volume Forecast by Country
13.2.1. Saudi Arabia
13.2.2. South Africa
13.2.3. UAE
13.2.4. Rest of Middle East & Africa (MEA)
13.3. Absolute $ Opportunity Assessment by Country
13.4. Middle East & Africa NGS-based RNA-seq Market Size and Volume Forecast by Application
13.4.1. Transcriptome Epigenetics
13.4.2. Small RNA
13.5. Basis Point Share (BPS) Analysis by Application
13.6. Y-o-Y Growth Projections by Application
13.7. Middle East & Africa NGS-based RNA-seq Market Size and Volume Forecast by Type
13.7.1. SBS
13.7.2. SMRT
13.8. Basis Point Share (BPS) Analysis by Type
13.9. Y-o-Y Growth Projections by Type
13.10. Market Attractiveness/Growth Potential Analysis
13.10.1. By Country
13.10.2. By Product Type
13.10.3. By Application
13.10.4. By Sales Channel
13.11. Middle East & Africa NGS-based RNA-seq Demand Share, 2019-2026
14. Competition Landscape
14.1. Global NGS-based RNA-seq Market: Market Share Analysis
14.2. NGS-based RNA-seq Distributors and Customers
14.3. NGS-based RNA-seq Market: Competitive Dashboard
14.4. Company Profiles (Details Overview, Financials, Developments, Strategy)
14.4.1. Illumina
14.4.1.1. Overview
14.4.1.2. Financials
14.4.1.3. Developments
14.4.1.4. Strategic Outlook
14.4.2. Thermo Fisher Scientific
14.4.2.1. Overview
14.4.2.2. Financials
14.4.2.3. Developments
14.4.2.4. Strategic Outlook
14.4.3. Pacific Biosciences Of California
14.4.3.1. Overview
14.4.3.2. Financials
14.4.3.3. Developments
14.4.3.4. Strategic Outlook
14.4.4. Qaigen
14.4.4.1. Overview
14.4.4.2. Financials
14.4.4.3. Developments
14.4.4.4. Strategic Outlook
14.4.5. F. Hoffmann-La Roche
14.4.5.1. Overview
14.4.5.2. Financials
14.4.5.3. Developments
14.4.5.4. Strategic Outlook
14.4.6. Agilent Technologies
14.4.6.1. Overview
14.4.6.2. Financials
14.4.6.3. Developments
14.4.6.4. Strategic Outlook
14.4.7. Oxford Nanopore Technologies
14.4.7.1. Overview
14.4.7.2. Financials
14.4.7.3. Developments
14.4.7.4. Strategic Outlook
14.4.8. Perkinelmer
14.4.8.1. Overview
14.4.8.2. Financials
14.4.8.3. Developments
14.4.8.4. Strategic Outlook
14.4.9. Eurofins Scientific
14.4.9.1. Overview
14.4.9.2. Financials
14.4.9.3. Developments
14.4.9.4. Strategic Outlook
14.4.10. Gatc Biotech
14.4.10.1. Overview
14.4.10.2. Financials
14.4.10.3. Developments
14.4.10.4. Strategic Outlook
14.4.11. Macrogen
14.4.11.1. Overview
14.4.11.2. Financials
14.4.11.3. Developments
14.4.11.4. Strategic Outlook
14.4.12. COMPANY 12
14.4.12.1. Overview
14.4.12.2. Financials
14.4.12.3. Developments
14.4.12.4. Strategic Outlook
14.4.13. COMPANY 13
14.4.13.1. Overview
14.4.13.2. Financials
14.4.13.3. Developments
14.4.13.4. Strategic Outlook
14.4.14. COMPANY 14
14.4.14.1. Overview
14.4.14.2. Financials
14.4.14.3. Developments
14.4.14.4. Strategic Outlook
14.4.15. COMPANY 15
14.4.15.1. Overview
14.4.15.2. Financials
14.4.15.3. Developments
14.4.15.4. Strategic Outlook
14.4.16. COMPANY 16
14.4.16.1. Overview
14.4.16.2. Financials
14.4.16.3. Developments
14.4.16.4. Strategic Outlook
14.4.17. COMPANY 17
14.4.17.1. Overview
14.4.17.2. Financials
14.4.17.3. Developments
14.4.17.4. Strategic Outlook
14.4.18. COMPANY 18
14.4.18.1. Overview
14.4.18.2. Financials
14.4.18.3. Developments
14.4.18.4. Strategic Outlook
14.4.19. COMPANY 19
14.4.19.1. Overview
14.4.19.2. Financials
14.4.19.3. Developments
14.4.19.4. Strategic Outlook
14.4.20. COMPANY 20
14.4.20.1. Overview
14.4.20.2. Financials
14.4.20.3. Developments
14.4.20.4. Strategic Outlook
